Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

Sponsor
Janssen-Cilag, S.A.
Study ID
NCT02414984
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Golimumab — BIOLOGICAL
    This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.

Study Details

The purpose of this study is to describe adherence to golimumab in Colombian participants with rheumatoid arthritis (RA) experiencing adequate treatment response, in a real-world clinical settings.

Key Dates

Start date
Mar 31, 2015
Status verified
Feb 2017
Primary completion
Nov 30, 2016
Completion
Nov 30, 2016

Study Design

Enrollment
37 participants (actual)

Arms

  • Arm: Golimumab
    Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.

Primary Outcome Measure

Treatment Adherence Measured by Continuous Measures of Medication Gaps (CMG) [ Time Frame: 24 months ]

Related Studies